Related Experiment Videos
Safety of human recombinant proteins
1Institute of Pathology, University of Basel, Switzerland.
Biomedical and Environmental Sciences : BES
|March 1, 1997
Summary
Recombinant protein therapies, while beneficial for stimulating hematopoiesis, require careful preclinical safety assessment. Toxicity studies in animals can predict potential adverse effects in humans, guiding safer therapeutic development.
Area of Science:
- Biotechnology
- Pharmacology
- Immunology
Background:
- Recombinant human proteins are vital therapeutics, particularly for stimulating hematopoiesis post-chemotherapy.
- Examples include erythropoietin and colony-stimulating factors, with others like IL-6 and IL-12 in development.
Purpose of the Study:
- To emphasize the necessity of preclinical safety assessment for recombinant protein therapeutics.
- To provide guidance for safety assessment based on existing protein data.
- To evaluate the predictive value of preclinical toxicity studies for human outcomes.
Main Methods:
- Review of existing data on recombinant protein therapies.
- Analysis of preclinical toxicity studies.
- Discussion of classical and novel safety testing approaches.
Main Results:
- Not all recombinant proteins are well-tolerated, contrary to initial assumptions.
- Preclinical toxicity studies demonstrate predictive value for human safety.
- Limitations of current safety testing methods were identified.
Conclusions:
- Preclinical safety evaluation is crucial for recombinant protein therapeutics.
- Established guidance and novel concepts can improve safety assessments.
- Animal toxicity data can inform human risk assessment for these therapies.